Extended Data Fig. 5: Additional characterization of plasma and PBMC from patients with neutralizing autoantibodies against IFN-I.
(a) IFN-I signaling (STAT1 phosphorylation measured by flow cytometry) was assessed across a range of plasma dilutions for the six patients with broadly-reactive IFN-I autoantibodies for IFNA2, IFNA4, and IFNA8 as described in the Methods. Experiment was conducted in duplicate with two technical replicates. The schematic was created using BioRender (https://biorender.com). (b) Related to Fig. 3c,d. Flow cytometry gating strategies for monocytes, dendritic cells, B cells, natural killer cells, regulatory T cells, non-regulatory CD4 T cells and CD8 T cells. Antibodies used for staining were listed in the methods. (c) Percentage of cells in each cluster for IFN-I autoantibody positive patients compared to control patients. (d) Related to Fig. 3f,g. Kaplan–Meier survival curves for mice bearing B16F10 (top) or CT26 (bottom) tumors under different treatment conditions. Figures reflect pooled results from two independent experiments with numbers of animals per group indicated in the legend. Significance was assessed by the log-rank test. (e) Related to Fig. 3h,i. Tumor weight-normalized analyses of T cell subpopulations in different treatment groups. Data points are representative of individual tumors measured in unicate. Significance was assessed using a two-sided Student’s t-test. (f) Related to Fig. 3h,i. Flow cytometry gating strategies for CD8+PD1+ T cells. Antibodies used for staining were listed in the methods.
